文献速递甲状腺疾病

嗜酸细胞性甲状腺癌的临床诊疗路径

Approach to the patient: Oncocytic thyroid cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

嗜酸细胞性甲状腺癌(OTC)是2022年WHO重新分类的独立甲状腺恶性肿瘤,具有线粒体DNA突变等独特分子特征,侵袭性亚型常伴血管侵犯和远处转移。细针穿刺难以可靠区分良恶性嗜酸细胞病变,分子检测可提高术前诊断准确性,但碘难治性疾病使系统治疗选择有限,酪氨酸激酶抑制剂和mTOR通路抑制剂证据尚有限。

要点

  • OTC是2022年WHO重新分类的独立实体,不同于滤泡性甲状腺癌。
  • 细针穿刺难以区分良恶性嗜酸细胞病变,分子检测可提高术前诊断准确性。
  • 侵袭性亚型血管侵犯和远处转移风险高,碘难治时系统治疗选择有限。

核心结论

  • OTC是独特的甲状腺恶性肿瘤实体,需改进诊断准确性、个体化治疗策略并扩大临床试验数据以优化结局。

研究设计与样本

  • 本文为临床实践指导类综述,总结OTC的分子特征、诊断工具和治疗选择。

主要发现

  • OTC具有线粒体DNA突变、体细胞变异负荷增加和广泛染色体杂合性缺失的独特分子特征。
  • 最侵袭性亚型显示高水平血管侵犯和转移扩散,主要为诊断时远处病变。
  • 细针穿刺不能可靠区分良性嗜酸细胞病变与恶性疾病,分子检测提高了术前诊断准确性。
  • 碘摄取差限制术后管理,许多患者为RAI难治性疾病,系统治疗选择有限。
  • 酪氨酸激酶抑制剂和mTOR通路抑制剂显示潜在获益但证据有限。

关键数值与推荐

  • 2022年WHO将OTC重新分类为独立临床实体。

临床怎么用

  • 术前评估应结合分子检测以提高嗜酸细胞病变良恶性鉴别准确性。
  • 对侵袭性亚型需关注血管侵犯和远处转移风险。
  • RAI难治性患者可考虑酪氨酸激酶抑制剂或mTOR通路抑制剂,但需认识证据有限。

局限性

  • 新兴疗法证据有限。
  • 需要扩大临床试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncocytic thyroid cancer (OTC), previously termed Hürthle cell carcinoma, is a rare but distinct thyroid malignancy. Although OTC arises from follicular epithelial cells and historically was classified as a subtype of follicular thyroid carcinoma, emerging molecular and clinical evidence demonstrates that OTC is distinct, leading to its reclassification by the World Health Organization (WHO) in 2022 into a separate clinical entity. OTC is characterized by a unique molecular landscape, including mitochondrial DNA mutations, increased somatic variant burden and widespread chromosomal loss of heterozygosity. Clinically, OTC presents with a spectrum of clinical behavior, with the most aggressive subtypes displaying high levels of vascular invasion and metastatic spread, mainly distant disease at the time of diagnosis. Diagnostic tools such as fine-needle aspiration can fail to reliably distinguish benign oncocytic lesions from malignant disease, complicating early evaluation and surgical decision-making, while the introduction of molecular testing has increased the accuracy of preoperative diagnostics. Poor radioiodine avidity further limits traditional postoperative management, leaving many patients with RAI-refractory disease few effective systemic treatment options. Emerging therapies, including tyrosine kinase inhibitors and mTOR pathway inhibitors, offer potential benefits but remain supported by limited evidence. As understanding of OTC continues to evolve, improving diagnostic accuracy, refining individualized treatment strategies, and expanding clinical trial data remain essential to optimizing outcomes for this distinct and often difficult to treat thyroid cancer.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Finnegan EA, Ganly I. Approach to the patient: Oncocytic thyroid cancer. J Clin Endocrinol Metab. 2026. PMID: 41603381. doi:10.1210/clinem/dgag025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。